ArticleFrontiers in immunology2025
The impact of sarcopenia on prognosis and fruquintinib efficacy in advanced colorectal cancer: a retrospective and mendelian randomization study.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Reportedly, sarcopenia is associated with prognosis in advanced colorectal cancer (CRC) patients and can lead to reduced efficacy of targeted therapy. However, studies on the relationship between sarcopenia and the prognosis (or efficacy) of advanced CRC patients receiving fruquintinib targeted therapy remains scarce. Therefore, we conducted a comprehensive assessment of the relationship between nutritional status, inflammation, immune function, and cancer-related sarcopenia. We also investigated whether sarcopenia affects the therapeutic efficacy of fruquintinib targeted therapy. Patients and methods: In this retrospective study, sarcopenia and several markers of nutritional status and immune function were assessed in advanced CRC patients with fruquintinib therapy at the hospital. We used drug target mendelian randomization (MR) analysis to investigate the impact of fruquintinib on sarcopenia. Results: Advanced CRC patients with sarcopenia had a poorer prognosis compared to those without sarcopenia. Furthermore, sarcopenia showed a strong correlation with various markers of nutritional status, immune function indicators, inflammation markers, quality of life scores, and the prognostic nutrition index. MR studies suggest that the spleen tyrosine kinase (SYK) gene is a key factor in the occurrence of sarcopenia associated with the use of fruquintinib. Conclusion: Sarcopenia could be a prognostic factor in patients with advanced CRC receiving fruquintinib targeted therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.